 John Curtin
Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 20 | 2020 | 407 | 2.280 |
Why?
| | Endometrial Neoplasms | 10 | 2019 | 151 | 1.960 |
Why?
| | Hysterectomy | 6 | 2018 | 118 | 1.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 13 | 2018 | 1361 | 0.950 |
Why?
| | Neoplasms, Glandular and Epithelial | 5 | 2016 | 39 | 0.880 |
Why?
| | Genital Neoplasms, Female | 3 | 2016 | 73 | 0.790 |
Why?
| | Neoadjuvant Therapy | 4 | 2019 | 301 | 0.650 |
Why?
| | Healthcare Disparities | 3 | 2018 | 486 | 0.630 |
Why?
| | Endometrial Hyperplasia | 5 | 2011 | 15 | 0.600 |
Why?
| | CA-125 Antigen | 1 | 2017 | 13 | 0.590 |
Why?
| | Papanicolaou Test | 1 | 2017 | 39 | 0.580 |
Why?
| | Watchful Waiting | 1 | 2017 | 57 | 0.570 |
Why?
| | Cytoreduction Surgical Procedures | 2 | 2018 | 40 | 0.550 |
Why?
| | Hospitals, Private | 1 | 2016 | 12 | 0.530 |
Why?
| | Hospitals, Public | 1 | 2016 | 23 | 0.530 |
Why?
| | Doxorubicin | 5 | 2012 | 290 | 0.520 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2017 | 154 | 0.510 |
Why?
| | Preoperative Period | 1 | 2016 | 104 | 0.510 |
Why?
| | Time-to-Treatment | 1 | 2016 | 147 | 0.480 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2016 | 863 | 0.430 |
Why?
| | Guideline Adherence | 1 | 2017 | 497 | 0.430 |
Why?
| | Gynecology | 3 | 2021 | 185 | 0.410 |
Why?
| | Neoplasm Staging | 7 | 2018 | 1178 | 0.390 |
Why?
| | Ovariectomy | 1 | 2011 | 117 | 0.380 |
Why?
| | Hospitals, Municipal | 1 | 2010 | 2 | 0.370 |
Why?
| | Polyethylene Glycols | 5 | 2012 | 576 | 0.370 |
Why?
| | Medical Oncology | 2 | 2015 | 230 | 0.360 |
Why?
| | Antineoplastic Agents | 5 | 2016 | 1893 | 0.330 |
Why?
| | Renal Insufficiency | 1 | 2010 | 137 | 0.320 |
Why?
| | Female | 42 | 2020 | 60018 | 0.320 |
Why?
| | Aged | 25 | 2020 | 19294 | 0.300 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 2393 | 0.300 |
Why?
| | Laparoscopy | 4 | 2018 | 400 | 0.290 |
Why?
| | Middle Aged | 28 | 2020 | 27069 | 0.280 |
Why?
| | TOR Serine-Threonine Kinases | 3 | 2016 | 362 | 0.280 |
Why?
| | Clinical Competence | 2 | 2010 | 912 | 0.280 |
Why?
| | Adenocarcinoma | 3 | 2011 | 799 | 0.280 |
Why?
| | Topotecan | 5 | 2013 | 14 | 0.280 |
Why?
| | Genetic Testing | 2 | 2020 | 382 | 0.260 |
Why?
| | Adult | 23 | 2020 | 30789 | 0.230 |
Why?
| | Multiprotein Complexes | 2 | 2016 | 145 | 0.230 |
Why?
| | Humans | 42 | 2021 | 115741 | 0.220 |
Why?
| | Adenosarcoma | 1 | 2002 | 3 | 0.210 |
Why?
| | Mixed Tumor, Mullerian | 1 | 2002 | 2 | 0.210 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2002 | 29 | 0.200 |
Why?
| | Financial Support | 1 | 2021 | 21 | 0.200 |
Why?
| | Health Care Sector | 1 | 2021 | 27 | 0.200 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 526 | 0.190 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2002 | 139 | 0.190 |
Why?
| | New York | 2 | 2011 | 109 | 0.190 |
Why?
| | Continuity of Patient Care | 1 | 2003 | 255 | 0.180 |
Why?
| | Length of Stay | 3 | 2016 | 958 | 0.180 |
Why?
| | Physical Examination | 2 | 2017 | 222 | 0.180 |
Why?
| | Obstetrics | 1 | 2021 | 161 | 0.170 |
Why?
| | Genetic Counseling | 1 | 2020 | 67 | 0.170 |
Why?
| | Aged, 80 and over | 11 | 2020 | 6423 | 0.170 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2016 | 638 | 0.170 |
Why?
| | Protein Kinase Inhibitors | 2 | 2016 | 790 | 0.170 |
Why?
| | Logistic Models | 4 | 2013 | 1856 | 0.160 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 241 | 0.160 |
Why?
| | Platinum | 2 | 2016 | 40 | 0.160 |
Why?
| | Jews | 2 | 2017 | 19 | 0.160 |
Why?
| | Disease Progression | 3 | 2016 | 2423 | 0.150 |
Why?
| | Bevacizumab | 3 | 2016 | 118 | 0.150 |
Why?
| | Survival Analysis | 3 | 2016 | 1219 | 0.140 |
Why?
| | Neoplasm Invasiveness | 2 | 2016 | 445 | 0.140 |
Why?
| | Organ Sparing Treatments | 1 | 2017 | 32 | 0.140 |
Why?
| | Organoplatinum Compounds | 2 | 2013 | 40 | 0.140 |
Why?
| | Sentinel Lymph Node | 1 | 2017 | 38 | 0.140 |
Why?
| | Fertility Preservation | 1 | 2017 | 47 | 0.140 |
Why?
| | Multigene Family | 1 | 2017 | 193 | 0.140 |
Why?
| | New York City | 3 | 2015 | 74 | 0.130 |
Why?
| | Mass Screening | 1 | 2003 | 1024 | 0.130 |
Why?
| | Symptom Assessment | 1 | 2017 | 121 | 0.130 |
Why?
| | Multimodal Imaging | 1 | 2017 | 99 | 0.130 |
Why?
| | Genes, BRCA2 | 2 | 2017 | 26 | 0.130 |
Why?
| | Genes, BRCA1 | 2 | 2017 | 33 | 0.130 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2016 | 48 | 0.130 |
Why?
| | Lymphatic Metastasis | 1 | 2017 | 276 | 0.130 |
Why?
| | Carboplatin | 5 | 2016 | 139 | 0.120 |
Why?
| | Mutation | 2 | 2017 | 3364 | 0.120 |
Why?
| | Tumor Burden | 1 | 2016 | 261 | 0.120 |
Why?
| | Cisplatin | 3 | 2013 | 263 | 0.120 |
Why?
| | Cyclonic Storms | 1 | 2015 | 35 | 0.120 |
Why?
| | Genital Diseases, Female | 1 | 2014 | 27 | 0.120 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2014 | 49 | 0.120 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1405 | 0.120 |
Why?
| | Disasters | 1 | 2015 | 88 | 0.120 |
Why?
| | Health Care Costs | 1 | 2017 | 384 | 0.110 |
Why?
| | Insurance, Health | 1 | 2016 | 246 | 0.110 |
Why?
| | Prognosis | 4 | 2016 | 3343 | 0.110 |
Why?
| | Hypotension, Orthostatic | 1 | 2013 | 8 | 0.110 |
Why?
| | Drug Administration Schedule | 2 | 2018 | 724 | 0.110 |
Why?
| | Photoplethysmography | 1 | 2013 | 16 | 0.110 |
Why?
| | Anxiety | 1 | 2020 | 854 | 0.110 |
Why?
| | BRCA2 Protein | 1 | 2013 | 42 | 0.110 |
Why?
| | BRCA1 Protein | 1 | 2013 | 57 | 0.110 |
Why?
| | Carcinoma, Endometrioid | 1 | 2013 | 47 | 0.110 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2013 | 44 | 0.110 |
Why?
| | Robotic Surgical Procedures | 1 | 2014 | 88 | 0.110 |
Why?
| | Pain, Postoperative | 1 | 2014 | 195 | 0.100 |
Why?
| | Paclitaxel | 2 | 2010 | 192 | 0.100 |
Why?
| | Blood Pressure Determination | 1 | 2013 | 123 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2017 | 12633 | 0.100 |
Why?
| | Karyometry | 1 | 2011 | 1 | 0.100 |
Why?
| | Muir-Torre Syndrome | 1 | 2011 | 2 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2016 | 9162 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2020 | 975 | 0.100 |
Why?
| | Depression | 1 | 2020 | 1147 | 0.100 |
Why?
| | Age Factors | 4 | 2013 | 2911 | 0.100 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2011 | 31 | 0.100 |
Why?
| | Recurrence | 2 | 2012 | 953 | 0.100 |
Why?
| | Platinum Compounds | 1 | 2010 | 11 | 0.090 |
Why?
| | Hysterectomy, Vaginal | 1 | 2010 | 7 | 0.090 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2011 | 114 | 0.090 |
Why?
| | Prospective Studies | 6 | 2020 | 6276 | 0.090 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2012 | 667 | 0.090 |
Why?
| | Phosphoproteins | 1 | 2011 | 304 | 0.080 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2018 | 334 | 0.080 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2011 | 374 | 0.080 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2011 | 213 | 0.080 |
Why?
| | Lymph Node Excision | 1 | 2009 | 141 | 0.080 |
Why?
| | Insurance Coverage | 1 | 2010 | 204 | 0.080 |
Why?
| | Thrombosis | 1 | 2012 | 302 | 0.080 |
Why?
| | Injections, Intraperitoneal | 3 | 2018 | 104 | 0.080 |
Why?
| | Cell Nucleus | 1 | 2011 | 553 | 0.080 |
Why?
| | Carcinoma in Situ | 1 | 2008 | 44 | 0.080 |
Why?
| | Cross-Sectional Studies | 3 | 2015 | 4448 | 0.080 |
Why?
| | Chromatin | 1 | 2011 | 429 | 0.080 |
Why?
| | Piperazines | 1 | 2010 | 314 | 0.080 |
Why?
| | Pyrimidines | 1 | 2010 | 376 | 0.070 |
Why?
| | Blood Pressure | 1 | 2013 | 1539 | 0.070 |
Why?
| | SEER Program | 1 | 2007 | 195 | 0.070 |
Why?
| | Quality of Life | 2 | 2014 | 2388 | 0.070 |
Why?
| | Biopsy | 2 | 2008 | 1056 | 0.070 |
Why?
| | Pathology | 1 | 2006 | 21 | 0.070 |
Why?
| | Hospitals, Community | 1 | 2006 | 47 | 0.060 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2010 | 577 | 0.060 |
Why?
| | Patient Care Planning | 1 | 2006 | 142 | 0.060 |
Why?
| | Everolimus | 2 | 2016 | 63 | 0.060 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 2 | 2016 | 57 | 0.060 |
Why?
| | Prevalence | 2 | 2013 | 2269 | 0.060 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 2 | 2016 | 99 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1265 | 0.060 |
Why?
| | Second-Look Surgery | 1 | 2003 | 7 | 0.060 |
Why?
| | Neoplasms | 1 | 2017 | 2118 | 0.060 |
Why?
| | Disease-Free Survival | 3 | 2010 | 621 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2016 | 704 | 0.050 |
Why?
| | Signal Transduction | 2 | 2013 | 4541 | 0.050 |
Why?
| | Injections, Intravenous | 2 | 2018 | 204 | 0.050 |
Why?
| | Survival Rate | 2 | 2018 | 1651 | 0.050 |
Why?
| | Endometriosis | 1 | 2002 | 41 | 0.050 |
Why?
| | Sirolimus | 2 | 2013 | 192 | 0.050 |
Why?
| | Fertility | 1 | 2002 | 131 | 0.050 |
Why?
| | Fallopian Tube Neoplasms | 2 | 2010 | 15 | 0.050 |
Why?
| | Patient Selection | 1 | 2004 | 654 | 0.050 |
Why?
| | Diagnostic Imaging | 1 | 2003 | 297 | 0.040 |
Why?
| | Carcinoma | 1 | 2002 | 200 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 941 | 0.040 |
Why?
| | Referral and Consultation | 2 | 2020 | 646 | 0.040 |
Why?
| | Floxuridine | 2 | 2013 | 7 | 0.040 |
Why?
| | Risk Factors | 3 | 2012 | 8702 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2002 | 1127 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2016 | 2751 | 0.040 |
Why?
| | Neutropenia | 2 | 2010 | 127 | 0.040 |
Why?
| | Biomarkers, Tumor | 1 | 2003 | 1048 | 0.040 |
Why?
| | Camptothecin | 1 | 2016 | 97 | 0.030 |
Why?
| | Allosteric Regulation | 1 | 2016 | 84 | 0.030 |
Why?
| | Family Health | 1 | 2017 | 195 | 0.030 |
Why?
| | Catalytic Domain | 1 | 2016 | 202 | 0.030 |
Why?
| | Liposomes | 2 | 2007 | 149 | 0.030 |
Why?
| | Disaster Planning | 1 | 2015 | 77 | 0.030 |
Why?
| | Operative Time | 1 | 2014 | 109 | 0.030 |
Why?
| | Cell Growth Processes | 1 | 2013 | 52 | 0.030 |
Why?
| | Infusion Pumps | 1 | 2013 | 32 | 0.030 |
Why?
| | Tilt-Table Test | 1 | 2013 | 7 | 0.030 |
Why?
| | Parents | 1 | 2002 | 1207 | 0.030 |
Why?
| | Sphygmomanometers | 1 | 2013 | 6 | 0.030 |
Why?
| | Ireland | 1 | 2013 | 25 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2013 | 58 | 0.030 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2013 | 46 | 0.030 |
Why?
| | Etoposide | 1 | 2013 | 149 | 0.030 |
Why?
| | Patient Positioning | 1 | 2013 | 43 | 0.030 |
Why?
| | Random Allocation | 1 | 2013 | 337 | 0.030 |
Why?
| | Cell Survival | 1 | 2016 | 1024 | 0.030 |
Why?
| | Heterozygote | 1 | 2013 | 252 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2013 | 244 | 0.030 |
Why?
| | Purines | 1 | 2013 | 159 | 0.030 |
Why?
| | Independent Living | 1 | 2013 | 84 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2013 | 501 | 0.030 |
Why?
| | Pain Measurement | 1 | 2014 | 449 | 0.030 |
Why?
| | Mice, Nude | 1 | 2013 | 639 | 0.030 |
Why?
| | Taxoids | 1 | 2012 | 94 | 0.020 |
Why?
| | Discriminant Analysis | 1 | 2011 | 39 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2013 | 400 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2012 | 286 | 0.020 |
Why?
| | Indoles | 1 | 2013 | 309 | 0.020 |
Why?
| | Deoxycytidine | 1 | 2012 | 140 | 0.020 |
Why?
| | Ascitic Fluid | 1 | 2010 | 14 | 0.020 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2010 | 16 | 0.020 |
Why?
| | United States | 2 | 2018 | 12304 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2013 | 1168 | 0.020 |
Why?
| | Infusions, Parenteral | 1 | 2010 | 38 | 0.020 |
Why?
| | Genes, erbB-1 | 1 | 2010 | 18 | 0.020 |
Why?
| | Young Adult | 2 | 2020 | 10518 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 962 | 0.020 |
Why?
| | Germ-Line Mutation | 1 | 2011 | 131 | 0.020 |
Why?
| | Imatinib Mesylate | 1 | 2010 | 64 | 0.020 |
Why?
| | Erlotinib Hydrochloride | 1 | 2010 | 65 | 0.020 |
Why?
| | Creatinine | 1 | 2012 | 430 | 0.020 |
Why?
| | Gene Amplification | 1 | 2010 | 96 | 0.020 |
Why?
| | Stomach Neoplasms | 1 | 2010 | 66 | 0.020 |
Why?
| | Lactones | 1 | 2010 | 56 | 0.020 |
Why?
| | Peritoneal Neoplasms | 1 | 2010 | 54 | 0.020 |
Why?
| | Remission Induction | 1 | 2010 | 240 | 0.020 |
Why?
| | Heart Rate | 1 | 2013 | 701 | 0.020 |
Why?
| | Benzamides | 1 | 2010 | 168 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 2011 | 390 | 0.020 |
Why?
| | Salvage Therapy | 1 | 2010 | 128 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1441 | 0.020 |
Why?
| | Recovery of Function | 1 | 2013 | 577 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2016 | 2194 | 0.020 |
Why?
| | Quinazolines | 1 | 2010 | 241 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2129 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1825 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2011 | 553 | 0.020 |
Why?
| | Phosphorylation | 1 | 2011 | 1571 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2018 | 2164 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2010 | 557 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2012 | 488 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 3580 | 0.020 |
Why?
| | DNA Topoisomerases, Type I | 1 | 2005 | 17 | 0.020 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2005 | 45 | 0.020 |
Why?
| | Nausea | 1 | 2005 | 103 | 0.020 |
Why?
| | Observer Variation | 1 | 2006 | 301 | 0.020 |
Why?
| | Vomiting | 1 | 2005 | 125 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2013 | 4442 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2005 | 374 | 0.010 |
Why?
| | Diarrhea | 1 | 2005 | 173 | 0.010 |
Why?
| | Phenotype | 1 | 2011 | 2839 | 0.010 |
Why?
| | Animals | 2 | 2016 | 32104 | 0.010 |
Why?
| | Aging | 1 | 2013 | 1632 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2004 | 249 | 0.010 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2003 | 84 | 0.010 |
Why?
| | Administration, Oral | 1 | 2005 | 734 | 0.010 |
Why?
| | Male | 3 | 2017 | 56050 | 0.010 |
Why?
| | Time Factors | 1 | 2013 | 6171 | 0.010 |
Why?
| | Risk Assessment | 1 | 2011 | 2990 | 0.010 |
Why?
| | Incidence | 1 | 2008 | 2335 | 0.010 |
Why?
| | Parity | 1 | 2002 | 99 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 1870 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2005 | 1642 | 0.010 |
Why?
| | Patient Participation | 1 | 2004 | 363 | 0.010 |
Why?
| | Cohort Studies | 1 | 2010 | 4949 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2004 | 961 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2006 | 2824 | 0.010 |
Why?
| | Mice | 1 | 2013 | 15052 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2002 | 3037 | 0.010 |
Why?
|
|
Curtin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|